Next Article in Journal
Nicotinamide, Nicotinamide Riboside and Nicotinic Acid—Emerging Roles in Replicative and Chronological Aging in Yeast
Previous Article in Journal
Tramesan Elicits Durum Wheat Defense against the Septoria Disease Complex
Previous Article in Special Issue
Photobiomodulation Mitigates Cerebrovascular Leakage Induced by the Parkinsonian Neurotoxin MPTP
Review

Photobiomodulation for Parkinson’s Disease in Animal Models: A Systematic Review

by 1,2,3 and 4,5,*
1
College for Light Medicine and Photobiomodulation, D-82319 Starnberg, Germany
2
Niraxx Light Therapeutics, Inc., Irvine, CA 92617, USA
3
ProNeuroLIGHT LLC, Phoenix, AZ 85083, USA
4
Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
5
Laser Research Centre, Faculty of Health Science, University of Johannesburg, 2028 Doornfontein, South Africa
*
Author to whom correspondence should be addressed.
Biomolecules 2020, 10(4), 610; https://doi.org/10.3390/biom10040610
Received: 24 March 2020 / Revised: 9 April 2020 / Accepted: 10 April 2020 / Published: 15 April 2020
(This article belongs to the Special Issue Photobiomodulation for Parkinson's Disease)
Photobiomodulation (PBM) might be an effective treatment for Parkinson’s disease (PD) in human patients. PBM of the brain uses red or near infrared light delivered from a laser or an LED at relatively low power densities, onto the head (or other body parts) to stimulate the brain and prevent degeneration of neurons. PD is a progressive neurodegenerative disease involving the loss of dopamine-producing neurons in the substantia nigra deep within the brain. PD is a movement disorder that also shows various other symptoms affecting the brain and other organs. Treatment involves dopamine replacement therapy or electrical deep brain stimulation. The present systematic review covers reports describing the use of PBM to treat laboratory animal models of PD, in an attempt to draw conclusions about the best choice of parameters and irradiation techniques. There have already been clinical trials of PBM reported in patients, and more are expected in the coming years. PBM is particularly attractive as it is a non-pharmacological treatment, without any major adverse effects (and very few minor ones). View Full-Text
Keywords: Parkinson’s disease; animal models; photobiomodulation; low-level laser therapy; transcranial; abscopal; parameters Parkinson’s disease; animal models; photobiomodulation; low-level laser therapy; transcranial; abscopal; parameters
Show Figures

Figure 1

MDPI and ACS Style

Salehpour, F.; Hamblin, M.R. Photobiomodulation for Parkinson’s Disease in Animal Models: A Systematic Review. Biomolecules 2020, 10, 610. https://doi.org/10.3390/biom10040610

AMA Style

Salehpour F, Hamblin MR. Photobiomodulation for Parkinson’s Disease in Animal Models: A Systematic Review. Biomolecules. 2020; 10(4):610. https://doi.org/10.3390/biom10040610

Chicago/Turabian Style

Salehpour, Farzad, and Michael R. Hamblin. 2020. "Photobiomodulation for Parkinson’s Disease in Animal Models: A Systematic Review" Biomolecules 10, no. 4: 610. https://doi.org/10.3390/biom10040610

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop